Ignite Creation Date:
2024-05-06 @ 8:18 PM
Last Modification Date:
2024-10-26 @ 3:25 PM
Study NCT ID:
NCT06331845
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-03-26
First Post:
2024-03-20
Brief Title:
Stop and go Strategy as First-line Treatment for Widely Metastatic Nasopharyngeal Carcinoma
Sponsor:
Fujian Cancer Hospital
Organization:
Fujian Cancer Hospital
Study Overview
Official Title:
Stop and go Strategy as First-line Treatment in Patients With Objective Response After Systematic Chemotherapy for Widely de Novo Metastatic Nasopharyngeal Carcinoma A Phase II Trial
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study aimed to investigate the value of a novel strategy of intermittent systematic chemotherapy ISC in widely metastatic nasopharyngeal carcinoma wmNPC patients who achieve objective response after systematic chemotherapy SC
Detailed Description:
Widely metastatic nasopharyngeal carcinoma wmNPC represented a particular subgroup of patients with the worst prognosis of which palliative systematic chemotherapySC was recommended as initial treatment however palliative systematic treatment was often required to be stopped due to the cumulative toxicities while stopping SC may lead to disease progression a stop and go approach namely chemotherapy holidays was a new strategy which may keep a good balance of benefit and risk This study aimed to investigate the value of a novel strategy of intermittent systematic chemotherapy ISC in wmNPC patients who achieve objective response after SC
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None